This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, C. Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat Biotechnol 29, 295–296 (2011). https://doi.org/10.1038/nbt0411-295
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0411-295
This article is cited by
-
Amgen announces oncolytic virus shrinks tumors
Nature Biotechnology (2013)
-
Regulating Cytokine Function Enhances Safety and Activity of Genetic Cancer Therapies
Molecular Therapy (2013)
-
Biotech's wellspring: a survey of the health of the private sector
Nature Biotechnology (2012)
-
Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression
Cancer Gene Therapy (2012)
-
Immunotherapeutic potential of oncolytic vaccinia virus
Immunologic Research (2011)